Carsten C. Skarke

faculty photo
Research Assistant Professor of Medicine
McNeil Fellow in Translational Medicine, Institute for Translational Medicine and Therapeutics
Department: Medicine

Contact information
Institute for Translational Medicine and Therapeutics (ITMAT)
8036 Maloney Building
3600 Spruce Street
Philadelphia, PA 19104
Office: (215) 746-8330
Fax: (215) 573-8996
MD (Medicine)
Johannes Gutenberg-University School of Medicine, Mainz, Germany, 1998.
Dr. med. (Pathology)
Johannes Gutenberg-University School of Medicine, Mainz, Germany, 2000.
Permanent link

Description of Itmat Expertise

Isoprostane Pharmacology – A particular interest is to elucidate the impact of grain alcohol and selected red wines on the formation of isoprostanes as indices of oxidative stress in humans with a dietary background conditioned by omega-3 and omega-6 polyunsaturated fatty acids, i.e. fish oil and safflower oil.

Eicosanoid Pharmacology – The current emphasis here is on studying the clinical pharmacology of a novel cyclooxygenase-2 (COX-2) inhibitor, which recently entered Phase I/II of its drug development program.

Pain / Inflammation – Here the focus is on applying pharmacokinetic, pharmacodynamic and pharmacogenetic tools to study the modulation of the drug response profile for cyclooxygenase (COX) inhibitors and opioid analgesics.

Clinical Research / Regulatory Science – Expertise in designing and implementing FDA-approved randomized-controlled clinical trials is applied to ongoing projects.

Translational Medicine and Therapeutics (TMAT) – A particular interest lies in the translational process of projecting preclinical research across the translational divide with the ultimate goal of developing novel therapeutics.

Selected Publications

Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, FitzGerald GA: Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther 91(6): 986-93, June 2012.

Skarke C, Kuczka K, Tausch L, Werz O, Rossmanith T, Barrett JS, Harder S, Holtmeier W, Schwarz JA: Increased bioavailability of 11‑keto-beta-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: Modeling and simulation considerations for evaluating drug exposures. J Clin Pharmacol 52(10): 1592-1600, October 2012.

Skarke Carsten, FitzGerald Garret A: Training translators for smart drug discovery. Science Translational Medicine. American Association for the Advancement of Science, 2(26): 26cm12, April 2010.

Skarke C, Schuss P, Kirchhof A, Doehring A, Geißlinger G, Lötsch J: PyrosequencingTM of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics 8(12): 1643-1660, December 2007.

Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G, Lötsch J: The cyclooxygenase-2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 80(6): 621-632, December 2006.

Skarke C, Geisslinger G, Lötsch J: Is morphine-3-glucuronide clinically important? Pain 116(3): 177-180, August 2005.

Skarke C, Langer M, Jarrar M, Schmidt H, Geisslinger G, Lötsch J: Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. Anesthesiology 101(6): 1394-1399, December 2004.

Skarke C, Kirchhof A, Geisslinger G, Lötsch J: Comprehensive mu-opioid-receptor genotyping by pyrosequencing. Clin Chem 50(3): 640-644, March 2004.

Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lötsch J: Effects of ABCB1 (multi drug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13(11): 651-660, November 2003.

Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J : Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74(4): 303-311, October 2003.

Skarke C, Schmidt H, Geisslinger G, Darimont J, Lötsch J: Pharmacokinetics of morphine are not altered in persons with Gilbert's syndrome. Brit J Clin Pharmacol 56(2): 228-231, August 2003.

Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73(1): 107-121, January 2003.

Lotsch J, Skarke C, Schmidt H, Liefhold J, Geisslinger G : Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clin Pharmacol Ther 72(2): 151-162, August 2002.

Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G: The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12(1): 3-9, January 2002.

Lotsch J, Skarke C, Schmidt H, Grosch S, Geisslinger G: The transfer half-life of morphine-6-beta-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers Anesthesiology 95(6): 1329-1338, December 2001.

back to top
Last updated: 10/17/2014
The Trustees of the University of Pennsylvania